The new biomarkers of prostate cancer;Les nouveaux marqueurs biologiques, du cancer de la prostate

Progres en Urologie

Volumn 21, Issue SUPPL. 2, 2011, Pages

  Bessede, Th ^a   Malavaud, B ^b  

^a BICÊTRE HOSPITAL   (France)

^b CHU RANGUEIL   (France)

Author keywords

Gene fusion; PCA3; Prostate Health Index; Risk marker

Indexed keywords

BIOLOGICAL MARKER; PROSTATE CANCER ANTIGEN 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

ARTICLE; BLOOD; HUMAN; MALE; PROSTATE TUMOR; URINE;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 79952585510     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1166-7087(11)70014-8     Document Type: Article

References (22)

1. Mazzola C.R., Ghoneim T., Shariat S.F. Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer. Prog Urol 2011, 21:1-10.
2. Graves H.C., Sensabaugh G.F., Blake E.T. Postcoital detection of a male-specific semen protein. Application to the investigation of rape. N Engl J Med 1985, 312:338-343.
3. Benson M.C., Whang I.S., Pantuck A., Ring K., Kaplan S.A., Olsson C.A., et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992, 147:815-816.
4. Sengupta S., Slezak J.M., Blute M.L., Bergstralh E.J. Simple graphic method for estimation of prostate-specific antigen doubling time. Urology 2006, 67:408-409.
5. MSKCC. Prostate Cancer Nomograms. ; 2006. http://wwwmskccorg/applications/nomograms/prostate/PsaDoublingTimeaspx.
6. Vickers A.J., Savage C., O'Brien M.F., Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009, 27:398-403.
7. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk:results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006, 98:529-534.
8. Parekh D.J., Ankerst D.P., Higgins B.A., Hernandez J., Canby-Hagino E., Brand T., et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 2006, 68:1152-1155.
9. Thompson IM. The New PCPT Prostate Cancer Calculator. ; 2010. http://debuthscsaedu/URORiskCalc/Pages/calcsPCA3jsp.
10. Benchikh El Fegoun A., Villers A. Molecular forms of PSA. Prog Urol 2007, 17:165-171.
11. Catalona W.J., Southwick P.C., Slawin K.M., Partin A.W., Brawer M.K., Flanigan R.C., et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000, 56:255-260.
12. Catalona WJ, Sanda MG, Wel JT, Klee GG, Slawin KM, Marks LS et al. ProPSA in combination with PSA and free-PSA, using the Beckman coulter access immunoassay systems improves prostate cancer detection relative to PSA and free PSA. A multi-center prospective clinical study. J of Urology 2010;183:in press.
13. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, et al. Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection. Eur Urol 2010;in press.
14. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999, 59:5975-5979.
15. Vlaeminck-Guillem V., Ruffion A., Andre J. Value of urinary PCA3 test for prostate cancer diagnosis. Prog Urol 2008, 18:259-265.
16. Reynolds M.A., Kastury K., Groskopf J., Schalken J.A., Rittenhouse H. Molecular markers for prostate cancer. Cancer Lett 2007, 249:5-13.
17. de Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002, 62:2695-2698.
18. Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008, 179:1587-1592.
19. Durand X., Xylinas E., Ploussard G., De la Taille A. Urinary biomarkers in prostate cancer: an update. Prog Urol 2010, 20:1184-1191.
20. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
21. Beuzeboc P., Soulie M., Richaud P., Salomon L., Staerman F., Peyromaure M., et al. Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives. Prog Urol 2009, 19:819-824.
22. Rice K.R., Chen Y., Ali A., Whitman E.J., Blase A., Ibrahim M., et al. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res 2010, 16:1572-1576.